This strategy allowed us to construct a new tool to measure the impact of a pediatric antimicrobial stewardship program, facilitating timely interventions and comparisons with historical antimicrobial usage. After analyzing the two methods of EC construction, we implemented GM and IC methods (10) because of the increased sensitivity to detect consumption variations. Different channels allowed us to establish a measure of central tendency and the path of the normal fluctuation of specific antimicrobial use during the year. At present, this kind of strategy has not been recommended as part of the ASP measurement tool by any policy statement or ASP guidelines.
Ceftriaxone: Concerning ceftriaxone, we could appreciate (Fig. 4A-B) an increase in its use compared with previous periods and years starting in December 2021, but especially in March 2022, when it almost reached the warning zone. During this period, at the hospital and as part of the evolution of the COVID-19 pandemic, children of all ages were reincorporated into the usual scholarly and social activities. At our hospital and in Bogota (11) similar to what has been described in other publications "new" behavior increased progressively emergency consults and hospitalizations related to respiratory diseases, including pneumonia, especially those caused by syncytial respiratory virus, rhinovirus, metapneumovirus, and a lesser degree SARS-CoV-2(12). Although penicillin was the first-line therapy in most cases when co-infection was suspected, some cases, especially during January and February, were associated with pneumococcal co-infection, complicated pneumonia, and some of them by resistant strains, as previously reported in Bogota. (13) As part of the ASP analysis and considering the endemic channel of ceftriaxone, we believe that part of this increase in ceftriaxone use was related to the increased severity of some identified cases, which led other clinicians to initiate ceftriaxone earlier. For this reason, from February to March, different educational strategies were implemented, and more intense ceftriaxone surveillance was performed. Although in April, we were still in a respiratory emergency, ceftriaxone use had declined in the last weeks. In this scenario, endemic channels allowed us to detect, analyze, and implement timely interventions to increase the use of ceftriaxone.
Piperacillin – tazobactam (PT): as reported in some latitudes, COVID-19 pandemic, related restrictions, and fear of parents to assist hospitals, contributed to increases in complicated appendicitis, including peritonitis, appendicular plastron, and septic shock of abdominal origin, (14–16) PT represents an alternative, especially in severe cases of intra-abdominal surgical complications, and this in part was the conclusion of our analyses because no other modification besides severity of patients was found. In August 2021, all COVID-19 restrictions were precluded in Colombia, and fewer cases of complicated appendicitis have been reported since then, possibly related to a more timely consultation in cases of abdominal pain, which contributed to the marked decrease in the use of PT. In this case, endemic channels allowed us to interpret prescription habits according to a population phenomenon described not only at our clinic (14–16). Historical comparison was important to detect these increases in DOT. Although major severity was considered the main cause of this PT increase, in January 2022, based on this finding, a new algorithm and educational strategies for intra-abdominal surgical infections were released at the institution to further optimize the use of PT.
Vancomycin is currently under strict surveillance, and we have noticed a progressive increase in the last year, especially related to severe methicillin-resistant S. aureus infections (prevalence > 42% at our center) and pneumococcal resistant infections. The increment identified this year was associated with severe cases of complicated pneumonia, without the identification of microbiological isolates and central nervous system infections. The considerable increase in PICU use compared to hospital use in general is related to the greater severity presented by this type of patient. More than 93% of prescriptions, according to ASP analysis, were considered adequate.
Concerning ampicillin-sulbactam, since January 2022, consumption has increased because of a change in the local recommendation (now is the first alternative in abdominal surgical prophylaxis), which explains this increase compared with previous years. This new recommendation implies that we need to update the EC according to new prescription habits and recommendations.
Recommendations about the implementation and interpretation of endemic channels from a Pediatric ASP:
• Use at least four years of DOT to construct endemic channels. This method is more convenient for implementation. Prefer the method of geometric means and confidence intervals over the method of median and quartiles, when computational capabilities allow it. Implementation of EC in critical services is fundamental.
• When detecting any zone change, we always try to identify the origin of this variation ( increase in cases, decline in local recommendation adherence, change in prescription habits, new personnel, and new recommendations).
• If any change in DOT to the alert zone is detected, it is recommended to implement strategies to increase the surveillance of that specific antibiotic. Attempt to identify the origin of this change and, if considered appropriate, initiate educational strategies or ASP measures necessary to contain this increase in the consumption of antibiotics.
• Update DOT, years included used to construct endemic channel when you modify local antimicrobial recommendations in the ASP for some antibiotics or when you identify modifications in previous use because of epidemiological findings or changes (e.g., increase in MDR pathogens).
• Reassess the consumption and tendency to define the necessity to update endemic channel graphs every 2–3 years.
• Present in periodic endemic channels not only in ASP committees and administrators, but also to clinicians to allow them to identify antimicrobial prescription habits across time.